Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
REPLICATION

Replication of Wild-Type and Mutant Human Cytomegalovirus in Life-Extended Human Diploid Fibroblasts

Wade A. Bresnahan, Gretchen E. Hultman, Thomas Shenk
Wade A. Bresnahan
Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544-1014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gretchen E. Hultman
Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544-1014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Shenk
Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544-1014
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.74.22.10816-10818.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A cDNA encoding the catalytic subunit of human telomerase was used to generate life-extended derivatives of primary human diploid fibroblasts. The life-extended cells supported efficient human cytomegalovirus (HCMV) replication. A subclone of the life-extended cells was generated containing the HCMV UL82 gene and used to isolate and propagate a virus that exhibited a profound growth defect after infection at a low input multiplicity.

Defining the molecular mechanisms that control human cytomegalovirus (HCMV) replication in vitro has been difficult in part due to the virus's limited host range. HCMV is typically propagated in primary cultures of human fibroblasts that yield relatively high titer stocks and produce plaques when infected with HCMV. However, primary human fibroblasts have a finite life span that limits their usefulness in studying HCMV replication. For example, it is difficult to generate stable fibroblast cell lines to complement defective HCMV strains. HCMV has been shown to replicate in a number of different cell types including human umbilical vein endothelial cells (4, 12, 13), macrophages and monocytes (5, 14), an astrocytoma cell line (3, 6), and a teratocarcinoma cell line (8). However, none of these cell lines produce high-titer stocks or plaques when infected with HCMV. Therefore, a life-extended fibroblast cell line capable of generating high-titer HCMV stocks and producing viral plaques would be a valuable tool to better understand the mechanisms of HCMV replication. It has recently been shown that constitutive expression of the catalytic subunit of human telomerase extends the life span of a number of somatic cells including human fibroblasts (2). We report here the generation of life-extended fibroblast clones that are fully permissive for HCMV replication and plaque formation. These life-extended fibroblasts have been used to generate a cell line that complements an HCMV mutant lacking the UL82 gene.

To generate life-extended human diploid foreskin fibroblasts (HFF cells), HFF-R2 cells at passage 6 were transfected with plasmid pGRN145 (2), which expresses the catalytic subunit of telomerase and a puromycin resistance marker. Stable clones were selected in puromycin (1 μg/ml) and analyzed for telomerase activity using the telomeric repeat amplification protocol (TRAP) assay (2, 7). We obtained 22 puromycin-resistant clones; 14 were negative and 8 were positive for telomerase activity (data not shown). We chose three positive and three negative clones for a more detailed analysis. Figure1 shows that clones 12, 16, and 18 were positive and clones 9, 10, and 13 were negative for telomerase activity in the TRAP assay. The parental cells (HFF-R2) were negative for telomerase activity. As a negative control, equivalent cell lysates from all samples were incubated at 85°C for 10 min to inactivate telomerase activity (2, 7). After heat inactivation, none of the samples expressed telomerase activity.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Telomerase activity in stable HFF clones. Stable HFF clones obtained by transfection with pGRN145 expressing the catalytic subunit of telomerase (Tel) were analyzed for telomerase activity by the TRAP assay using a TRAPEZE kit (Intergen) according to the manufacturer's instructions. Two thousand cells were analyzed in all samples. TRAP products were separated by gel electrophoresis (11.25% polyacrylamide) and detected by autoradiography. As a negative control, cell lysates were incubated at 85°C for 10 min (ΔH) to inactivate telomerase. TSR8, positive control for the PCR; IC, internal control for all reactions.

We compared the proliferative life spans of the telomerase-positive and -negative clones. Once clones were expanded to a 10-cm-diameter dish, the population doubling was set at 40. Cells were counted and passed every 5 to 7 days, and new population doublings were calculated. As shown in Fig. 2, the three telomerase-negative clones underwent senescence, i.e., failed to double within 2 weeks, between population doublings 45 and 55. All 14 telomerase-negative clones senesced after 49.4 (±3.0) population doublings (data not shown). In contrast, the three telomerase-positive clones have exceeded 135 population doublings and continue to divide like early-passage HFF cells.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Replicative life span of telomerase-positive and -negative clones. Cells were counted and passaged every 5 to 7 days, and new population doublings were calculated. Cultures were considered senescent (*) if they had undergone less than one population doubling in 2 weeks.

To determine if expression of telomerase affected the ability of HCMV to replicate and produce high-titer stocks, three telomerase-negative and three telomerase-positive clones were infected with HCMV (strain AD169) at a multiplicity of infection (MOI) of 5 PFU/cell, and virus titers were compared to those in HCMV-infected parental HFF cells. Telomerase negative clones 9, 10, and 13 were tested at population doublings 47 to 48.5, prior to undergoing senescence. HCMV replication in telomerase-positive clones 12, 16, and 18 were tested at both lower (46.5 to 51) and higher (65 to 75) population doublings, to determine if there was a difference in viral titers at different passage levels. As shown in Table 1, telomerase-positive and -negative cells were equally permissive for HCMV replication, and the three telomerase-positive clones yielded similar titers at lower or higher population doublings. There was no difference in the yield of HCMV in the parental HFF cells, telomerase-negative clones, or telomerase-positive clones.

View this table:
  • View inline
  • View popup
Table 1.

Comparison of wild-type HCMV growth on telomerase-positive and telomerase-negative cell linesa

We next compared HCMV gene expression in telomerase-positive clones to that in the parental HFF cells. Expression of the immediate-early 1 (IE1) protein and the UL99 (pp28) late protein were examined in HFF and telomerase 18 cells at various times after infection. As shown in Fig.3, the expression level and kinetics for IE1 and pp28 are identical between the two cell lines. Similar results were obtained with telomerase-positive clones 12 and 16 (data not shown). To ensure that all telomerase cells in culture were permissive for HCMV, HFF and telomerase 18 cells were infected at an MOI of 5 PFU/cell and stained 72 h postinfection for expression of the late antigen pp28. Over 95% of HFF and telomerase 18 cells stained positive for pp28 expression (data not shown).

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

Comparison of immediate-early and late gene expression in HFF and telomerase-positive cells. HFF or telomerase 18 cells were infected with HCMV at an MOI of 5. Cell lysates were prepared at the indicated times postinfection (P.I.), and 50 μg of protein from each sample was analyzed by Western blotting using antibodies against either IE1 (Chemicon 810) or pp28 (9, 11).

To demonstrate that the life-extended fibroblasts could be used to complement a defective HCMV mutant, we generated a derivative clone expressing the HCMV UL82 (pp71) gene product. UL82 was chosen because previous attempts to propagate a UL82 deletion mutant have been unsuccessful in our laboratory, suggesting that UL82 may be required for efficient HCMV replication (data not shown). UL82 was put under the control of the HCMV UL99 promoter to inhibit expression of UL82 in the absence of HCMV infection, thereby ameliorating a potential detrimental effect of UL82 on cell growth. The UL82 (pp71) expression vector was constructed by using oligonucleotides (5′-AGATCTGCGCCGGCGTCTCGCCGGGCATC-3′ and 5′-GCTAGCCACGTTGAGCCGGCCCAGCAGCTC-3′) for PCR amplification of the UL99 promoter from HCMV AD169 viral DNA and cloned into the pGEMT-Easy vector (Promega). A BglII/NheI fragment containing the UL99 promoter was cloned into the pCI-neo vector (Promega) that had been digested withBglII/NheI. The resulting plasmid, pWF28, replaced the HCMV immediate-early enhancer/promoter with the UL99 promoter. The UL82 cDNA containing a hemagglutinin tag was then amplified from pCGN71 (1) using oligonucleotides (5′-CTATGGCTTCTAGCTATCCTTATGAC-3′ and 5′-CTCTAGATGCGGGGTCGACTGCG), cloned into the pGEMT-Easy vector, and sequenced. The tagged cDNA was removed via EcoRI digestion and cloned intoEcoRI-digested pWF28. The resulting plasmid, pWF28-71-HA, was then transfected into telomerase 12 cells via electroporation (260 V, 960 μF) at population doubling 60 and cultured in the presence of 400 μg of G418 per ml. G418-resistant clones were selected and screened for UL82 expression. A UL82 deletion virus (ADsubUL82) was then purified and propagated on one stable clone (WF28-71-HA) expressing UL82. ADsubUL82 was generated by homologous recombination using a previously described insertion cassette (10) containing the green fluorescent protein. This cassette was flanked by sequences corresponding to nucleotides 116666 to 117628 and 119206 to 120278 of the HCMV AD169 genome. This cassette containing the UL82 flanking sequences was then transfected into HFF cells together with infectious AD169 viral DNA. Green fluorescent plaques were picked, purified on WF28-71-HA cells, and screened by Southern blotting and PCR amplification to ensure that we had obtained a pure virus stock and correct recombination.

The mutant virus was then assayed for its ability to replicate on noncomplementing HFF cells compared to complementing WF28-71-HA cells. HFF or WF28-71-HA cells were infected at an MOI of 0.01 PFU/ml with either wild-type AD169 or ADsubUL82, and viral titers were determined at 21 days postinfection. As shown in Table2, the wild-type virus gave rise to similar titers on both HFF and WF28-71-HA cells. In contrast, ADsubUL82 did not grow on the noncomplementing HFF cells but yielded near-wild-type titers on the complementing WF28-71-HA cells (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Comparison of wild-type and ΔUL82 viral titers on complementing and noncomplementing cell linesa

In conclusion, life-extended fibroblasts supported the efficient replication of HCMV and provided the opportunity to generate derivative cell clones expressing viral genes that are useful for the propagation of mutant viruses.

ACKNOWLEDGMENTS

We thank Geron Corporation for pGRN145.

This work was supported by grant CA82396 from the National Cancer Institute. W.A.B. is supported by an NIH postdoctoral fellowship.

FOOTNOTES

    • Received 7 July 2000.
    • Accepted 21 August 2000.
  • Copyright © 2000 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Baldick C. J. Jr.,
    2. Marchini A.,
    3. Patterson C. E.,
    4. Shenk T.
    Human cytomegalovirus tegument protein pp71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle.J. Virol. 71 1997 4400 4408
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Bodnar A. G.,
    2. Ouellette M.,
    3. Frolkis M.,
    4. Holt S. E.,
    5. Chiu C. P.,
    6. Morin G. B.,
    7. Harley C. B.,
    8. Shay J. W.,
    9. Lichtsteiner S.,
    10. Wright W. E.
    Extension of life-span by introduction of telomerase into normal human cells.Science 279 1998 349 352
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Boeckh M.,
    2. Gleaves C. A.,
    3. Bindra R.,
    4. Meyers J. D.
    Comparison of MRC-5 and U-373MG astrocytoma cells for detection of cytomegalovirus in shell vial centrifugation cultures.Eur. J. Clin. Microbiol. Infect. Dis. 10 1991 569 572
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Ho D. D.,
    2. Rota T. R.,
    3. Andrews C. A.,
    4. Hirsch M. S.
    Replication of human cytomegalovirus in endothelial cells.J. Infect. Dis. 150 1984 956 957
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Ibanez C. E.,
    2. Schrier R.,
    3. Ghazal P.,
    4. Wiley C.,
    5. Nelson J. A.
    Human cytomegalovirus productively infects primary differentiated macrophages.J. Virol. 65 1991 6581 6588
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Kari B.,
    2. Radeke R.,
    3. Gehrz R.
    Processing of human cytomegalovirus envelope glycoproteins in and egress of cytomegalovirus from human astrocytoma cells.J. Gen. Virol. 73 1992 253 260
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Kim N. W.,
    2. Piatyszek M. A.,
    3. Prowse K. R.,
    4. Harley C. B.,
    5. West M. D.,
    6. Ho P. L.,
    7. Coviello G. M.,
    8. Wright W. E.,
    9. Weinrich S. L.,
    10. Shay J. W.
    Specific association of human telomerase activity with immortal cells and cancer.Science 266 1994 2011 2015
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. LaFemina R.,
    2. Hayward G. S.
    Constitutive and retinoic acid-inducible expression of cytomegalovirus immediate-early genes in human teratocarcinoma cells.J. Virol. 58 1986 434 440
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Nowak B.,
    2. Sullivan C.,
    3. Sarnow P.,
    4. Thomas R.,
    5. Bricout F.,
    6. Nicolas J. C.,
    7. Fleckenstein B.,
    8. Levine A. J.
    Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins.Virology 132 1984 325 338
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Patterson C. E.,
    2. Shenk T.
    Human cytomegalovirus UL36 protein is dispensable for viral replication in cultured cells.J. Virol. 73 1999 7126 7131
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Romanowski M. J.,
    2. Garrido-Guerrero E.,
    3. Shenk T.
    pIRS1 and pTRS1 are present in human cytomegalovirus virions.J. Virol. 71 1997 5703 5705
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Span A. H.,
    2. Mullers W.,
    3. Miltenburg A. M.,
    4. Bruggeman C. A.
    Cytomegalovirus induced PMN adherence in relation to an ELAM-1 antigen present on infected endothelial cell monolayers.Immunology 72 1991 355 360
    OpenUrlPubMedWeb of Science
  13. 13.↵
    1. Waldman W. J.,
    2. Roberts W. H.,
    3. Davis D. H.,
    4. Williams M. V.,
    5. Sedmak D. D.,
    6. Stephens R. E.
    Preservation of natural endothelial cytopathogenicity of cytomegalovirus by propagation in endothelial cells.Arch. Virol. 117 1991 143 164
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Weinshenker B. G.,
    2. Wilton S.,
    3. Rice G. P.
    Phorbol ester-induced differentiation permits productive human cytomegalovirus infection in a monocytic cell line.J. Immunol. 140 1988 1625 1631
    OpenUrlAbstract
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Replication of Wild-Type and Mutant Human Cytomegalovirus in Life-Extended Human Diploid Fibroblasts
Wade A. Bresnahan, Gretchen E. Hultman, Thomas Shenk
Journal of Virology Nov 2000, 74 (22) 10816-10818; DOI: 10.1128/JVI.74.22.10816-10818.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Replication of Wild-Type and Mutant Human Cytomegalovirus in Life-Extended Human Diploid Fibroblasts
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Replication of Wild-Type and Mutant Human Cytomegalovirus in Life-Extended Human Diploid Fibroblasts
Wade A. Bresnahan, Gretchen E. Hultman, Thomas Shenk
Journal of Virology Nov 2000, 74 (22) 10816-10818; DOI: 10.1128/JVI.74.22.10816-10818.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

cytomegalovirus
Fibroblasts
mutation

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514